Psychedelic-inspired Medicines are Paving the Way for Major Gains in Psychedelic Stocks like Minerco inc (OTC: MINE)

As psychedelic-inspired medicines laid the groundwork for the first psychedelic medicine, a nasal spray called Spravato, used for the treatment of depression, to clear U.S. Food and Drug Administration approval in March 2019, changing science, consumer attitude and changing laws are paving the way for major gains in psychedelic stocks.

The psychedelic market just took a massive step towards legitimacy in the eye of corporate America. Earlier this month, the U.K.-based pharmaceutical company Compass Pathways became the first psychedelic company to break into U.S. markets. The news is a big step towards the legitimacy of the legal psychedelic marketplace—which is forecasted to be nearly a $6.9 billion business by 2027.

Minerco, Inc. (OTC: MINE), is the world’s first publicly traded company specializing in growing, research, production and distribution of psilocybin mushrooms and marketing worldwide.

The company tweeted a few pictures on its twitter account yesterday:


Last month, Minerco announced that the company is looking to open facility in Ann Arbor Michigan. MINE is now poised to take advantage of the Midwest market.

This is an exciting development for us to be one the the first companies to open a facility in the Midwest. Magic Mushrooms can heal so many people and provide a first mover advantage for our company ,” stated Julius Jenge, Chief Executive Officer of Minerco, Inc. Our commitment to research, production and distribution of psilocybin mushrooms, is now a reality, Minerco can be poised to help PSTD and work closer with Doctors in Ann Arbor. Michigan being the second largest medical Cannabis state in USA gives us an additional opportunity to thrive for our shareholders.

Any investor who avoided psychedelic stocks over the past two years would be well served to take another look. Right now could well be the opportunity you’ve been waiting for. But if you wait until the money is rolling in, the share price will likely have already risen to reflect a more traditional valuation and the opportunity for huge gains will be gone.